A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Summary

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Timeline

Start

2025-10-15

Primary completion

2030-03-06

Completion

2030-03-06

Drugs

Indications